Literature DB >> 3579664

Intramedullary spinal cord metastasis. Diagnostic and therapeutic considerations.

M D Winkelman, D J Adelstein, N L Karlins.   

Abstract

The diagnosis of intramedullary spinal cord metastasis (ISM) is difficult, and treatment is usually ineffective. We review our own experience with ISM as well as the pertinent medical literature, and suggest a practical diagnostic and therapeutic approach. The problem of the diagnosis of ISM is essentially that of the differential diagnosis of a noncompressive myelopathy in a patient with systemic cancer. Most such patients prove to have ISM, meningeal carcinomatosis, radiation myelopathy, or paraneoplastic necrotizing myelopathy. Neurologic features of value in this differential diagnosis are pain, the tempo and mode of progression of symptoms, and tumor cells in the spinal fluid. Oncologic features of value are the location of the primary tumor, the past exposure to therapeutic radiation, cerebral metastases, and the extent of systemic metastatic disease. The myelogram in ISM is either normal or nonspecifically abnormal; therefore, the diagnosis must be made on clinical grounds. Although no single finding is diagnostic of ISM, a careful clinical analysis will lead to the correct diagnosis in most cases. Radiation therapy is effective treatment for ISM, but only if it is administered early, before paraplegia supervenes. Thus, the diagnosis should be made and treatment begun as soon as possible. Intramedullary spinal cord metastasis is often multifocal rather than solitary; therefore, whole-cord rather than local spinal radiation should be given, if possible. If local radiotherapy is chosen, the construction of the portal can be based on the myelogram or, in the event of a normal study, on the clinical localization of the tumor.

Entities:  

Mesh:

Year:  1987        PMID: 3579664     DOI: 10.1001/archneur.1987.00520170054022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

1.  Intramedullary metastasis of unknown origin: a case report.

Authors:  A Raco; R Delfini; M Salvati; G Innocenzi; P Ciappetta
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

Review 2.  Pure intramedullary spinal cord metastasis secondary to gastric cancer.

Authors:  Roberto Gazzeri; Marcelo Galarza; Andrea Faiola; Giovanni Gazzeri
Journal:  Neurosurg Rev       Date:  2006-02-08       Impact factor: 3.042

Review 3.  Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature.

Authors:  Christos Kosmas; Maria Koumpou; Maria Nikolaou; John Katselis; Georgia Soukouli; Nina Markoutsaki; Vassiliki Kostopoulou; Assimina Gaglia; Nikolaos Mylonakis; Athanassios Karabelis; Dimitrios Pectasides
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 4.  Surgical indications and prognosis in spinal metastases.

Authors:  K Nanassis; C Alexiadou-Rudolf; J Rudolf; R A Frowein
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

5.  Intramedullary spinal cord metastasis following a slowly progressive course.

Authors:  J H Koelman; M De Visser; J A Kuster; J J Dreissen; J Valk; P A Koster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

6.  Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report.

Authors:  Kester A Phillips; Elizabeth Gaughan; Alejandro Gru; David Schiff
Journal:  CNS Oncol       Date:  2017-10-16

7.  MRI diagnosis of intramedullary metastases from extra-CNS tumors.

Authors:  S Crasto; S Duca; O Davini; L Rizzo; I G Pavanello; T Avataneo; S Cirillo; D Regge; R Soffietti
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

Review 8.  Hemangioblastomas and other uncommon intramedullary tumors.

Authors:  D J Miller; I E McCutcheon
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 9.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.